 SALT LAKE CITY, Feb. 25, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries, Clene today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, will present blinded interim data from its VISIONARY-MS study and updated interim data from its REPAIR-MS study in on-demand presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS ACTRIMS Forum 2021 taking place virtually from February 25-27, 2021. Together, these complementary Phase 2 studies evaluate the efficacy, safety, and central nervous system CNS metabolic effects of Clenes lead drug candidate CNM-Au8, a bioenergetic nanocatalyst, in multiple sclerosis MS patients. 